221 related articles for article (PubMed ID: 26192545)
1. Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.
Marks MJ; O'Neill HC; Wynalda-Camozzi KM; Ortiz NC; Simmons EE; Short CA; Butt CM; McIntosh JM; Grady SR
Neuropharmacology; 2015 Dec; 99():142-55. PubMed ID: 26192545
[TBL] [Abstract][Full Text] [Related]
2. The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.
de Moura FB; McMahon LR
Psychopharmacology (Berl); 2017 Mar; 234(5):781-792. PubMed ID: 28028600
[TBL] [Abstract][Full Text] [Related]
3. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
4. Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.
Metaxas A; Al-Hasani R; Farshim P; Tubby K; Berwick A; Ledent C; Hourani S; Kitchen I; Bailey A
Neuropharmacology; 2013 Aug; 71():228-36. PubMed ID: 23583933
[TBL] [Abstract][Full Text] [Related]
5. CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.
Sala M; Braida D; Pucci L; Manfredi I; Marks MJ; Wageman CR; Grady SR; Loi B; Fucile S; Fasoli F; Zoli M; Tasso B; Sparatore F; Clementi F; Gotti C
Br J Pharmacol; 2013 Feb; 168(4):835-49. PubMed ID: 22957729
[TBL] [Abstract][Full Text] [Related]
6. α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration.
Marks MJ; Grady SR; Salminen O; Paley MA; Wageman CR; McIntosh JM; Whiteaker P
J Neurochem; 2014 Jul; 130(2):185-98. PubMed ID: 24661093
[TBL] [Abstract][Full Text] [Related]
7. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
Bagdas D; Alkhlaif Y; Jackson A; Carroll FI; Ditre JW; Damaj MI
Neuropharmacology; 2018 Aug; 138():72-79. PubMed ID: 29860196
[TBL] [Abstract][Full Text] [Related]
8. Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
Ortiz NC; O'Neill HC; Marks MJ; Grady SR
Nicotine Tob Res; 2012 Jun; 14(6):711-9. PubMed ID: 22241831
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of the beta4 neuronal nicotinic receptor subunit affects tolerance development and nicotinic binding sites following chronic nicotine treatment.
Meyers EE; Loetz EC; Marks MJ
Pharmacol Biochem Behav; 2015 Mar; 130():1-8. PubMed ID: 25560939
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys.
Withey SL; Doyle MR; Bergman J; Desai RI
J Pharmacol Exp Ther; 2018 Aug; 366(2):397-409. PubMed ID: 29784663
[TBL] [Abstract][Full Text] [Related]
11. Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control.
Rollema H; Russ C; Lee TC; Hurst RS; Bertrand D
Nicotine Tob Res; 2014 Jun; 16(6):733-42. PubMed ID: 24406270
[TBL] [Abstract][Full Text] [Related]
12. Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography.
Nguyen HN; Rasmussen BA; Perry DC
J Pharmacol Exp Ther; 2003 Dec; 307(3):1090-7. PubMed ID: 14560040
[TBL] [Abstract][Full Text] [Related]
13. Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists: scheduled-controlled responding and hypothermia in C57BL/6J mice.
de Moura FB; McMahon LR
Behav Pharmacol; 2016 Apr; 27(2-3 Spec Issue):240-8. PubMed ID: 26910582
[TBL] [Abstract][Full Text] [Related]
14. Differential cross-tolerance to the effects of nicotinic acetylcholine receptor drugs in C57BL/6J mice following chronic varenicline.
de Moura FB; McMahon LR
Behav Pharmacol; 2019 Aug; 30(5):412-421. PubMed ID: 30398980
[TBL] [Abstract][Full Text] [Related]
15. Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain.
Marks MJ; McClure-Begley TD; Whiteaker P; Salminen O; Brown RW; Cooper J; Collins AC; Lindstrom JM
J Pharmacol Exp Ther; 2011 Apr; 337(1):187-200. PubMed ID: 21228066
[TBL] [Abstract][Full Text] [Related]
16. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
[TBL] [Abstract][Full Text] [Related]
18. AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology.
Cippitelli A; Wu J; Gaiolini KA; Mercatelli D; Schoch J; Gorman M; Ramirez A; Ciccocioppo R; Khroyan TV; Yasuda D; Zaveri NT; Pascual C; Xie XS; Toll L
Br J Pharmacol; 2015 Apr; 172(7):1834-45. PubMed ID: 25440006
[TBL] [Abstract][Full Text] [Related]
19. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
Smith JW; Mogg A; Tafi E; Peacey E; Pullar IA; Szekeres P; Tricklebank M
Psychopharmacology (Berl); 2007 Feb; 190(2):157-70. PubMed ID: 17115136
[TBL] [Abstract][Full Text] [Related]
20. Anti-smoking drugs cytisine and varenicline reduce cardiac reperfusion injury in rat model of myocardial ischemia.
Shaykhutdinova ER; Severyukhina MS; Kholoshenko IV; Gondarenko EA; Shelukhina IV; Kryukova EV; Ismailova AM; Sadovnikova ES; Dyachenko IA; Murashev AN; Tsetlin VI; Utkin YN
Biochimie; 2024 Jan; 216():108-119. PubMed ID: 37871826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
